Calamos Advisors LLC Has $47.79 Million Stock Position in Pfizer Inc. $PFE

Calamos Advisors LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,919,276 shares of the biopharmaceutical company's stock after purchasing an additional 58,944 shares during the period. Calamos Advisors LLC's holdings in Pfizer were worth $47,790,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the company. State Street Corp boosted its holdings in shares of Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock worth $7,620,747,000 after acquiring an additional 2,786,098 shares during the period. Northern Trust Corp boosted its stake in shares of Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock valued at $1,631,225,000 after buying an additional 869,175 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock valued at $1,255,860,000 after buying an additional 897,786 shares during the period. Legal & General Group Plc boosted its stake in shares of Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock valued at $1,063,565,000 after buying an additional 3,296,415 shares during the period. Finally, Amundi boosted its stake in shares of Pfizer by 10.8% in the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company's stock valued at $1,096,380,000 after buying an additional 4,043,413 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE opened at $27.01 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $153.56 billion, a P/E ratio of 19.86 and a beta of 0.43. The firm's fifty day simple moving average is $27.23 and its two-hundred day simple moving average is $26.06. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. During the same quarter in the prior year, the firm posted $0.63 earnings per share. The business's quarterly revenue was down 1.2% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio is 126.47%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PFE shares. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an "underweight" rating and a $25.00 price objective for the company. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an "outperform" rating and a $33.00 price objective for the company. HSBC boosted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. BMO Capital Markets restated an "outperform" rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Finally, Morgan Stanley boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of "Hold" and an average price target of $28.48.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; ex-div May 8), reinforcing Pfizer’s long track record of income (350th consecutive quarterly dividend) and supporting demand from income-minded investors. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Seagen acquisition appears to be contributing to growth and a stronger oncology franchise (Antibody‑Drug Conjugates), supporting medium-term revenue upside as Pfizer expands cancer capabilities. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: GLP‑1 obesity program momentum — Phase 2b monthly GLP‑1 data and plans for a large clinical program provide optionality beyond legacy drugs and could open a new growth engine if later‑stage trials succeed. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Positive Sentiment: Multiple early‑stage pipeline advances (completion of a China Phase 1 for a heart‑failure candidate, new gastric‑emptying study for an obesity asset, new Phase 1 cancer and liver studies) add cadence and long‑term upside to the pipeline. Pfizer Advances Early-Stage Heart Failure Candidate With Completion Of Chinese Phase 1 Study
• Neutral Sentiment: Pfizer released results from its 2026 shareholder meeting — largely procedural items that don’t materially change near‑term fundamentals. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Bristol Myers and Pfizer will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27 — improves patient access but raises questions about pricing/volume tradeoffs; watch margin impact. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
• Neutral Sentiment: Broader industry news — competitors (e.g., Eli Lilly, Novo Nordisk) continue to shape the obesity/GLP‑1 landscape; this is both competitive risk and market validation for Pfizer’s obesity push. Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
• Negative Sentiment: Pfizer ended a Phase 1 cancer trial, trimming part of its oncology pipeline — a reminder that not all program investments convert to later‑stage value and a near‑term negative headline. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism persists (Barclays remains negative; consensus leans to “hold”), which can cap upside until clearer revenue/cost trajectories emerge. Barclays Remains a Sell on Pfizer (PFE)

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.